-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Some time ago, the National Medical Insurance Drug List was officially released in 2021, and 74 new drugs were added to the list
.
Among them, a number of Class 1 new drugs entered medical insurance for the first time
.
Such as Zejing Pharmaceutical's oral multi-target, multi-kinase inhibitor small molecule anti-tumor drug Donafenib tosylate tablets, and Iris' EGFR (epidermal growth factor receptor tyrosine kinase) inhibitor methanesulfonic acid Vomitinib tablets, Aidi Pharmaceuticals' HIV infection antiviral drug Ainovirin tablets, and Hisun Pharmaceutical's oral intestinal cholesterol absorption inhibitor Haibo Maibu tablets are all included for the first time
.
It is worth mentioning that a number of varieties have just been approved for marketing within the year
.
For example, Hansen Pharmaceutical’s new class 1 hepatitis B drug Hengmu® (imitenofovir tablets) (TMF) was just approved for marketing in China on June 22, 2021, and it entered successfully after only 5 months.
Medicare, for the treatment of adult patients with chronic hepatitis
.
It is understood that imitenofovir tablets are a new type of nucleotide reverse transcriptase inhibitors, which inhibit reverse transcriptase in a similar way to nucleoside reverse transcriptase inhibitors, thereby simultaneously having potential anti-HIV- 1 activity
.
Early clinical research results confirmed that the drug is well tolerated and safe in healthy volunteers and patients with chronic hepatitis B (CHB), and the PK characteristics and efficacy are in line with expectations
.
This time, its smooth access to health insurance, will help improve China-made innovative pharmaceutical drugs accessibility and affordability, benefit more hepatitis B patients
.
In addition, Mengke Pharmaceutical's antibacterial product, Contizolamide, which entered the medical insurance catalog this time, was also approved for marketing through the priority review and approval procedure of the National Medical Products Administration on June 1 this year
.
In addition, BeiGene's PARP (polyadenosine diphosphate ribose polymerase) inhibitor Pamipali capsules were just approved in early May
.
In this regard, analysts believe that compared with the past 8 years of non-adjustment of the medical insurance catalogue, there are more and more domestic new drugs entering the medical insurance with the smooth flow of the "routine action"; it is obvious that the innovation ability of domestic pharmaceutical companies There has been a significant improvement, and these innovative drugs are gaining more and more recognition
.
In this context, as more new drugs will be included in medical insurance
.
The industry believes that the level of domestic drug security will be significantly improved, and the availability of drugs will also be further improved, benefiting more patients; at the same time, it will also force China's pharmaceutical companies to accelerate innovation and promote the sustained and high-quality development of China's innovative drug industry
.
Generally speaking, the industry generally believes that in order to effectively reduce the burden of people’s drug costs and meet the medical needs of the people, it is necessary to rely on independent innovation and truly firmly control the safety of medical and health strategies and the people’s right to price for medical treatment
.
Therefore, the majority of pharmaceutical companies must seize major opportunities such as medical insurance catalog adjustments, consistency evaluations, and volume purchases, and make good use of favorable policies such as registration system reforms, drug marketing authorization holder systems, and accelerating new drug approvals to speed up the development and production of new drugs.
, To accelerate the upgrading of the industrial structure, and strive to win more development opportunities in innovative development
.
.
Among them, a number of Class 1 new drugs entered medical insurance for the first time
.
Such as Zejing Pharmaceutical's oral multi-target, multi-kinase inhibitor small molecule anti-tumor drug Donafenib tosylate tablets, and Iris' EGFR (epidermal growth factor receptor tyrosine kinase) inhibitor methanesulfonic acid Vomitinib tablets, Aidi Pharmaceuticals' HIV infection antiviral drug Ainovirin tablets, and Hisun Pharmaceutical's oral intestinal cholesterol absorption inhibitor Haibo Maibu tablets are all included for the first time
.
It is worth mentioning that a number of varieties have just been approved for marketing within the year
.
For example, Hansen Pharmaceutical’s new class 1 hepatitis B drug Hengmu® (imitenofovir tablets) (TMF) was just approved for marketing in China on June 22, 2021, and it entered successfully after only 5 months.
Medicare, for the treatment of adult patients with chronic hepatitis
.
It is understood that imitenofovir tablets are a new type of nucleotide reverse transcriptase inhibitors, which inhibit reverse transcriptase in a similar way to nucleoside reverse transcriptase inhibitors, thereby simultaneously having potential anti-HIV- 1 activity
.
Early clinical research results confirmed that the drug is well tolerated and safe in healthy volunteers and patients with chronic hepatitis B (CHB), and the PK characteristics and efficacy are in line with expectations
.
This time, its smooth access to health insurance, will help improve China-made innovative pharmaceutical drugs accessibility and affordability, benefit more hepatitis B patients
.
In addition, Mengke Pharmaceutical's antibacterial product, Contizolamide, which entered the medical insurance catalog this time, was also approved for marketing through the priority review and approval procedure of the National Medical Products Administration on June 1 this year
.
In addition, BeiGene's PARP (polyadenosine diphosphate ribose polymerase) inhibitor Pamipali capsules were just approved in early May
.
In this regard, analysts believe that compared with the past 8 years of non-adjustment of the medical insurance catalogue, there are more and more domestic new drugs entering the medical insurance with the smooth flow of the "routine action"; it is obvious that the innovation ability of domestic pharmaceutical companies There has been a significant improvement, and these innovative drugs are gaining more and more recognition
.
In this context, as more new drugs will be included in medical insurance
.
The industry believes that the level of domestic drug security will be significantly improved, and the availability of drugs will also be further improved, benefiting more patients; at the same time, it will also force China's pharmaceutical companies to accelerate innovation and promote the sustained and high-quality development of China's innovative drug industry
.
Generally speaking, the industry generally believes that in order to effectively reduce the burden of people’s drug costs and meet the medical needs of the people, it is necessary to rely on independent innovation and truly firmly control the safety of medical and health strategies and the people’s right to price for medical treatment
.
Therefore, the majority of pharmaceutical companies must seize major opportunities such as medical insurance catalog adjustments, consistency evaluations, and volume purchases, and make good use of favorable policies such as registration system reforms, drug marketing authorization holder systems, and accelerating new drug approvals to speed up the development and production of new drugs.
, To accelerate the upgrading of the industrial structure, and strive to win more development opportunities in innovative development
.
